686 related articles for article (PubMed ID: 7994757)
21. Increase in tumor necrosis factor-alpha mRNA but not perforin mRNA expression in response to two newly characterized anti-LFA-1 monoclonal antibodies.
Hommel-Berrey G; Bochan M; Brahmi Z
Nat Immun; 1994; 13(6):301-14. PubMed ID: 7894201
[TBL] [Abstract][Full Text] [Related]
22. Soluble HLA class I molecules in malignant pleural and peritoneal effusions and its possible role on NK and LAK cytotoxicity.
Amirghofran Z; Sheikhi AK; Kumar PV; Saberi Firouzi M
J Cancer Res Clin Oncol; 2002 Aug; 128(8):443-8. PubMed ID: 12200601
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of term decidual NK cell cytotoxicity by soluble HLA-G1.
Poehlmann TG; Schaumann A; Busch S; Fitzgerald JS; Aguerre-Girr M; Le Bouteiller P; Schleussner E; Markert UR
Am J Reprod Immunol; 2006; 56(5-6):275-85. PubMed ID: 17076671
[TBL] [Abstract][Full Text] [Related]
24. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.
Ghio M; Contini P; Negrini S; Boero S; Musso A; Poggi A
Eur J Immunol; 2009 Dec; 39(12):3459-68. PubMed ID: 19830740
[TBL] [Abstract][Full Text] [Related]
25. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
26. Studies of sublines selected for loss of HLA expression from an EBV-transformed lymphoblastoid cell line. Changes in sensitivity to cytotoxic T cells activated by allostimulation and natural killer cells activated by IFN or IL-2.
Ohlén C; Bejarano MT; Grönberg A; Torsteinsdottir S; Franksson L; Ljunggren HG; Klein E; Klein G; Kärre K
J Immunol; 1989 May; 142(9):3336-41. PubMed ID: 2468716
[TBL] [Abstract][Full Text] [Related]
27. Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor.
Lagoo-Deenadayalan S; Lagoo AS; Hardy KJ; Grimm EA
Lymphokine Cytokine Res; 1992 Aug; 11(4):207-13. PubMed ID: 1420599
[TBL] [Abstract][Full Text] [Related]
28. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
29. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
30. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
31. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4.
Salvucci O; Mami-Chouaib F; Moreau JL; Thèze J; Chehimi J; Chouaib S
Eur J Immunol; 1996 Nov; 26(11):2736-41. PubMed ID: 8921963
[TBL] [Abstract][Full Text] [Related]
32. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood.
Harris DT
Bone Marrow Transplant; 1995 Jan; 15(1):17-23. PubMed ID: 7742753
[TBL] [Abstract][Full Text] [Related]
35. Evidence for an early calcium-independent event in the activation of the human natural killer cell cytolytic mechanism.
Brahmi Z; Bray RA; Abrams SI
J Immunol; 1985 Dec; 135(6):4108-13. PubMed ID: 3864859
[TBL] [Abstract][Full Text] [Related]
36. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of lymphokine-activated killer- and natural killer-mediated cytotoxicities by neutrophils.
Shau HY; Golub SH
J Immunol; 1989 Aug; 143(3):1066-72. PubMed ID: 2787346
[TBL] [Abstract][Full Text] [Related]
38. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
39. Human cytotoxic effector cells: definition and analysis of activity.
Ortaldo JR
Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
